- Home
- OABI vs NMAI Comparison
OABI vs NMAI Comparison
Compare OABI & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- NMAI
- Stock Information
- Founded
- OABI 2012
- NMAI 2021
- Country
- OABI United States
- NMAI United States
- Employees
- OABI N/A
- NMAI N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- NMAI Investment Managers
- Sector
- OABI Health Care
- NMAI Finance
- Exchange
- OABI Nasdaq
- NMAI Nasdaq
- Market Cap
- OABI 388.5M
- NMAI 399.1M
- IPO Year
- OABI N/A
- NMAI N/A
- Fundamental
- Price
- OABI $3.22
- NMAI $12.30
- Analyst Decision
- OABI Strong Buy
- NMAI
- Analyst Count
- OABI 4
- NMAI 0
- Target Price
- OABI $9.00
- NMAI N/A
- AVG Volume (30 Days)
- OABI 448.8K
- NMAI 74.8K
- Earning Date
- OABI 11-12-2024
- NMAI 01-01-0001
- Dividend Yield
- OABI N/A
- NMAI 13.14%
- EPS Growth
- OABI N/A
- NMAI N/A
- EPS
- OABI N/A
- NMAI 0.64
- Revenue
- OABI $20,409,000.00
- NMAI N/A
- Revenue This Year
- OABI N/A
- NMAI N/A
- Revenue Next Year
- OABI $78.61
- NMAI N/A
- P/E Ratio
- OABI N/A
- NMAI $19.03
- Revenue Growth
- OABI N/A
- NMAI N/A
- 52 Week Low
- OABI $3.16
- NMAI $10.60
- 52 Week High
- OABI $6.55
- NMAI $12.55
- Technical
- Relative Strength Index (RSI)
- OABI 32.70
- NMAI 55.19
- Support Level
- OABI $3.16
- NMAI $11.85
- Resistance Level
- OABI $3.29
- NMAI $12.25
- Average True Range (ATR)
- OABI 0.13
- NMAI 0.12
- MACD
- OABI -0.02
- NMAI 0.05
- Stochastic Oscillator
- OABI 9.09
- NMAI 98.89
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.